Discontinuation of ANtihypertensive Treatment in Older people with dementia living in a Nursing home

Completed

Conditions: dementia
neuropsychiatric symptoms
10012272

Registration Number: NL-OMON50258

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 492

Inclusion Criteria

Eligible to participate in this study, a subject must meet all of the following
criteria:
• being admitted in nursing home
• have a diagnosis of moderate to severe dementia according to the Reisberg
Global Deterioration Scale (score 5-6-7)
• are currently on antihypertensive treatment with a calcium antagonist,
diuretic, ACE-inhibitor, beta-blocker or angiotensin-II-receptor blocker
prescribed for hypertension
• have a systolic blood pressure <=160mmHg (average of two last blood pressure
measurements)

Exclusion Criteria

An potential subject who meets any of the following criteria will be excluded
from participation:
• recent (<12 months) history of myocardial infarction, stroke, coronary
reperfusion procedures (CABG/PCI)
• heart failure NYHA class III or IV
• current angina pectoris
• have a life-expectancy less than 4 months.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The co-primary outcome measures are the differences in change of scores between<br /><br>0 and 4 months on the Neuropsychiatric Inventory - Nursing Homes (NPI-NH) and<br /><br>quality of life (Qualidem).<br /><br><br /><br>Long-term effects on primary and secondary outcomes will be analysed over 8<br /><br>months</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcome measures include NPS registered in the medical records, care<br /><br>dependency, cognitive function, general daily functioning, care-related quality<br /><br>of life, orthostatic hypotension, incident falls, and psychotropic medication<br /><br>use.<br /><br><br /><br>Long-term effects on primary and secondary outcomes will be analysed over 8<br /><br>months. In addition, cost-effectiveness will be evaluated.</p><br>